Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map
Complete the form below to unlock access to ALL audio articles.
Compendia Bioscience, Inc. has announced the release and immediate availability of Oncomine™ Concepts Map, a high-value product extension of Compendia’s flagship product Oncomine™ Professional.
Oncomine Concepts Map (OCM) combines nearly 7,000 Oncomine cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.
The technology uses gene sets as a common language to compare and link disparate biological concepts, as recently described in the journal Neoplasia. A second study published in Nature Genetics used Oncomine Concepts Map to analyze prostate cancer gene expression in the context of the other gene signatures available in OCM. The result was an important new model describing the progression of prostate cancer.
The Company says that three major biotech and pharmaceutical companies have already committed to licensing Oncomine Concepts Map on top of their existing Oncomine licenses, and many additional companies are actively evaluating the technology.
